Genmab — Maj 2023

[E_L]

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. https://meetings.asco.org/abstracts-presentations/218272 -Seems odd that double-hit/triple-hit lymphoma is doing as well as other patients in the trial?

[E_L]

Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool. https://meetings.asco.org/abstracts-presentations/226499 In 2L recurrent disease, all experts chose either single-agent immunotherapy (if PD-L1 positive) or tisotumab vedotin (if PD-L1 negative) vs 45% and 40% of HCPs, respectively

[Darvin]

thanks E L - sounds fantastic, or rather fantastic. Epco's future looks somewhat better than the market expects so far. .

[E_L]

I think so too. But it will be hard keeping up with all the trials and cohorts and different subsets etc they are planning lol...

[E_L]

and i didn't check the abstracts for Dara , Talquetamab , teclistamab and amivantamab yet...

[gentogen]

Thanks EL. This really is KYSO!

[Stroka]

Thanks E L.

[E_L]

I think you should thank Genmab, not me lol

[paundal]

E L. You deserve a thank you. Thank you for your posts, which are always relevant and qualified. You always keeping your eyes on the ball!

[gentogen]

I very much agree. By the way, this is another very interesting initiative from Genmab: https://anthropology.ku.dk/dep/news/2021/biotech-company-funds-research-project-on-diversity/

[gentogen]

old news, I must admit, but I had not seen it before

[E_L]

SVB Securities analyst Jonathan Chang reiterated a Hold rating on Genmab (GMAB – Research Report) on May 25 and set a price target of $40.

[Riis7]

Ser ud til det forsætter med at folk skifter over i tech og væk fra Pharma

[JKY_VH]

Pendulet skal nok svinge den anden vej igen;-

[Klarussen]

Der er forårsudsalg i Genmab, virker lidt voldsomt

[gdn55]

Der er åbentbart negativt at få en godkendelse på en ny medicin, der på sigt kan give ligeså meget , som Dara giver nu. Men sådan er der jo så meget, jeg ikke forstår i denne verden

[Klarussen]

Ja, det virker ikke logisk. Ser ud som om den vender nu for idag. Jeg har suppleret lidt og fortsætter med at supplere hvis den skulle falde yderligere. Ser dog ud som om den stadig ligger i den kortsigtede, stigende trendkanal fra 10/3 2023

[Pensionisten]

Det er, en lidt anden form for KYSO

[Riis7]

Tech og Big tech fik tæsk i 2022 hvor Pharma vandt , det er så omvendt i år:-) se bare nvidia der tæt på et afkast på 200%
bare i år:-)

[gdn55]

Ja sådan er der jo meget. Købte Genmab i 2011. Har et afkast på ca. 7500%. Hvis jeg har regnet rigtigt giver det et afkast på 625% pr. år.